Mehr Stanton R, Zimmerman Marj P
President, SM Health Communications, Newtown, PA.
President, RxDirections, Bucyrus, KS.
Am Health Drug Benefits. 2015 Nov;8(8):426-31.
Significant innovations in the treatment of patients with multiple sclerosis (MS) have primarily addressed the frequency of flare-ups in relapsing-remitting MS (RRMS). Many advances have been made in this area, and the medical community may be on the verge of a serious discussion of what constitutes a truly effective MS treatment. Certainly, it is important to further delay MS flare-ups and more effectively treat RRMS symptoms. However, great strides in reducing or preventing MS-related disability and providing neuroprotection have been elusive. Many unmet needs are still voiced by patients with MS, clinicians, and caregivers. Current information on the need for progress in various areas is reviewed in this article, including psychosocial care, treatments for progressive MS, biomarker identification, functional outcome measures, individualization of treatment, reducing side effects of medications, and improving medication adherence.
多发性硬化症(MS)患者治疗方面的重大创新主要针对复发缓解型多发性硬化症(RRMS)的发作频率。该领域已取得诸多进展,医学界可能即将展开一场关于何为真正有效MS治疗的严肃讨论。当然,进一步延缓MS发作并更有效地治疗RRMS症状很重要。然而,在减少或预防MS相关残疾以及提供神经保护方面取得的巨大进展却难以实现。MS患者、临床医生和护理人员仍表达了许多未满足的需求。本文综述了当前关于各个领域取得进展必要性的信息,包括心理社会护理、进行性MS的治疗、生物标志物识别、功能结局测量、治疗个体化、减少药物副作用以及提高药物依从性。